Clinical Trial Update: Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating canrenone as add-on therapy for moderate to severe ARDS in COVID-19 patients; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Acute Respiratory Distress Syndrome

Drugs mentioned

• Canrenone (canrenone)

Snippet

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Conditions: COVID-19 Acute Respiratory Distress Syndrome | Phase 2 | Status: UNKNOWN